ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 178

Fc-Gamma Receptor Genetic Variation In Kawasaki Disease

Carline E. Tacke1,2, Willemijn B. Breunis3,4, Long T. Hoang1, Eileen Png1, Judy Geissler5, Sietse Nagelkerke4, Justine Ellis6,7, Sonia Davila8, Chiea Chuen Khor8, Michael Levin9, David Burgner10,11, Chisato Shimizu12, Jane C. Burns12, Martin L. Hibberd1 and Taco W. Kuijpers4,13, 1Infectious Diseases, Genome Institute of Singapore, Singapore, Singapore, 2Pediatric Hematology, Immunology and Infectious Diseases, Emma Children's Hospital/Academic Medical Center (AMC), Amsterdam, Netherlands, 3Pediatric rheumatology and immunology, Emma Children's Hospital/Academic Medical Center (AMC), Amsterdam, Netherlands, 4Blood cell research, Sanquin Resarch and Landsteiner Laboratory (AMC), Amsterdam, Netherlands, 5Sanquin Resarch and Landsteiner Laboratory (AMC), Amsterdam, Netherlands, 6Murdoch Childrens Research Institute, Parkville, Australia, 7Department of Paediatrics, The University of Melbourne, Parkville, Australia, 8Human Genetics, Genome Institute of Singapore, Singapore, Singapore, 9Department of Pediatrics, Imperial College London, London, United Kingdom, 10The royal Children's Hospital, Murdoch Childrens Research Institute, Parkville, Australia, 11Department of Paediatrics, The University of Melbourne, Melbourne, Australia, 12Pediatrics, UC San Diego, School of Medicine, La Jolla, CA, 13Pediatric Rheumatology and Immunology, Emma Children's Hospital/Academic Medical Center (AMC), Amsterdam, Netherlands

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Fc receptors, Kawasaki disease and polymorphism

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Genetics and Genomics of Rheumatic Disease I

Session Type: Abstract Submissions (ACR)

Abstract on behalf of the International Kawasaki Disease Genetics Consortium.

Background/Purpose: Kawasaki disease (KD) is a pediatric vasculitis of unknown etiology with a substantial genetic contribution to susceptibility. KD is complicated by coronary artery aneurysms in 25% of untreated patients. Intravenous immunoglobulin (IVIG), a polyclonal IgG preparation, decreases the aneurysm rate to <10%. In our recent GWAS, a functional variant in FCGR2A (131H>R; rs1801274) was associated with KD at genome-wide significance. FCGR2A encodes the Fc-gamma receptor (FcγR) IIa, one member of a family of glycoproteins on leukocytes that bind the Fc-domain of IgG. The balance between the various activating and a single inhibiting FcγR (FcγRIIb) determines the level of cell activation. Hence, altered FcγR expression may result in unbalanced immunity or auto-inflammation. FCGR2A is located within the FCGR2/3 gene cluster. This cluster contains extensive gene copy number variations (CNVs) and several important single nucleotide polymorphisms (SNPs). We hypothesized that CNV and additional SNPs within the FCGR locus, regulating gene transcription and expression of the FcγRs, may be important in KD susceptibility.

Methods: The FCGR-specific Multiplex-Ligation Probe-dependent Amplification (MLPA) assay was performed in 426 patients and 710 controls of Caucasian origin, and in 510 patient-parent trios of mixed ethnic origin. First, the association between FCGR genotype status (including CNV, FCGR2A-131H>R, FCGR2A-27Q>W, FCGR2C-ORF and FCGR2B -386G>C) and KD susceptibility was analyzed. Second, the genetic variation at the FCGR2/3 locus was correlated to the expression of these genes. Transcriptional expression data (pre-IVIG acute and post-IVIG convalescent samples) were available in a subset of 169 patients.

Results: An increased allele frequency of the open-reading frame (ORF) of FCGR2C encoding an additional activating FcγRIIc was found in patients as compared to controls (OR 1.4 [95%CI 1.1-1.7], p=0.016). We also observed a significant overrepresentation of FCGR2A-27Q>W (OR 1.5 [95%CI 1.1-1.9, p=0.006) and the -386G>C promoter polymorphism of FCGR2B and FCGR2C (OR 1.5 [95%CI 1.1-1.9], p=0.004) in KD. No significant difference was found in the allele frequency of FCGR2A-131H>R in KD patients and controls (43.8% versus 45.4%, p=0.467). The frequency of CNV in the FCGR2C, FCGR3A and FCGR3B genes was not significantly different between the groups. A positive correlation was observed between gene expression and dosage of FCGR2C, FCGR3A and FCGR3B, which may affect the activating FcγRs expression level on leucocytes. Results of the patient-parent trios data using transmission disequilibrium tests (TDT) will be used for further validation of our fine-mapping studies on the FCGR2/3genes in KD.

Conclusion: A significant overrepresentation of FCGR2C-ORF, as well as FCGR2A-27Q>W and the FCGR2B/C-386G>C promoter polymorphisms, was observed in Caucasian KD patients compared to the controls. Genetic variation at the FCGR2/3 gene cluster may lead to a shift in the balance towards the activating FcγRs and may therefore contribute to the development of the inflammatory response in KD.


Disclosure:

C. E. Tacke,
None;

W. B. Breunis,
None;

L. T. Hoang,
None;

E. Png,
None;

J. Geissler,
None;

S. Nagelkerke,
None;

J. Ellis,
None;

S. Davila,
None;

C. C. Khor,
None;

M. Levin,
None;

D. Burgner,
None;

C. Shimizu,
None;

J. C. Burns,
None;

M. L. Hibberd,
None;

T. W. Kuijpers,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fc-gamma-receptor-genetic-variation-in-kawasaki-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology